Laboratory of Medical Genetics Unit, "Bambino Gesù" Children's Hospital, IRCCS, Viale di San Paolo 15, 00146, Rome, Italy.
Department of Pediatrics, Tuscany Regional Centre for Cystic Fibrosis, Anna Meyer Children's Hospital, Florence, Italy.
Mol Med. 2018 Jul 27;24(1):38. doi: 10.1186/s10020-018-0041-6.
Recurrent (RP) and chronic pancreatitis (CP) may complicate Cystic Fibrosis (CF). It is still unknown if mutations in genes involved in the intrapancreatic activation of trypsin (IPAT) or in the pancreatic secretion pathway (PSP) may enhance the risk for RP/CP in patients with CF.
We enrolled: 48 patients affected by CF complicated by RP/CP and, as controls 35 patients with CF without pancreatitis and 80 unrelated healthy subjects. We tested a panel of 8 genes involved in the IPAT, i.e. PRSS1, PRSS2, SPINK1, CTRC, CASR, CFTR, CTSB and KRT8 and 23 additional genes implicated in the PSP.
We found 14/48 patients (29.2%) with mutations in genes involved in IPAT in the group of CF patients with RP/CP, while mutations in such genes were found in 2/35 (5.7%) patients with CF without pancreatitis and in 3/80 (3.8%) healthy subjects (p < 0.001). Thus, we found mutations in 12 genes of the PSP in 11/48 (22.9%) patients with CF and RP/CP. Overall, 19/48 (39.6%) patients with CF and RP/CP showed one or more mutations in the genes involved in the IPAT and in the PSP while such figure was 4/35 (11.4%) for patients with CF without pancreatitis and 11/80 (13.7%) for healthy controls (p < 0.001).
The trans-heterozygous association between CFTR mutations in genes involved in the pathways of pancreatic enzyme activation and the pancreatic secretion may be risk factors for the development of recurrent or chronic pancreatitis in patients with CF.
复发性(RP)和慢性胰腺炎(CP)可能使囊性纤维化(CF)复杂化。目前尚不清楚参与胰酶(IPAT)内在激活或胰腺分泌途径(PSP)的基因突变是否会增加 CF 患者发生 RP/CP 的风险。
我们纳入了 48 例 CF 合并 RP/CP 的患者作为研究对象,将 35 例无胰腺炎 CF 患者和 80 名无关健康对照作为对照组。我们检测了一组 8 个参与 IPAT 的基因(PRSS1、PRSS2、SPINK1、CTRC、CASR、CFTR、CTSB 和 KRT8)和 23 个参与 PSP 的其他基因的突变。
我们发现 48 例 CF 合并 RP/CP 患者中有 14 例(29.2%)存在 IPAT 相关基因的突变,而无胰腺炎 CF 患者中有 2 例(5.7%)和健康对照中有 3 例(3.8%)存在此类基因突变(p<0.001)。因此,我们在 11/48(22.9%)例 CF 合并 RP/CP 患者中发现了 PSP 中 12 个基因的突变。总体而言,19/48(39.6%)例 CF 合并 RP/CP 患者在 IPAT 和 PSP 相关基因中存在一个或多个突变,而在无胰腺炎 CF 患者中为 4/35(11.4%),在健康对照中为 11/80(13.7%)(p<0.001)。
参与胰腺酶激活途径和胰腺分泌途径的 CFTR 基因突变的反杂合子关联可能是 CF 患者发生复发性或慢性胰腺炎的危险因素。